Naomi Deirdre Fisher, M.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Renin | 35 | 2022 | 636 | 3.300 |
Why?
|
| Hypertension | 43 | 2024 | 8595 | 2.540 |
Why?
|
| Renin-Angiotensin System | 25 | 2017 | 739 | 1.990 |
Why?
|
| Angiotensin II | 27 | 2017 | 850 | 1.720 |
Why?
|
| Renal Circulation | 26 | 2017 | 292 | 1.680 |
Why?
|
| Cacao | 7 | 2013 | 98 | 1.550 |
Why?
|
| Blood Pressure | 33 | 2024 | 8523 | 1.230 |
Why?
|
| Flavonoids | 5 | 2012 | 444 | 1.130 |
Why?
|
| Sympathectomy | 6 | 2024 | 90 | 1.040 |
Why?
|
| Fumarates | 6 | 2016 | 131 | 1.020 |
Why?
|
| Captopril | 17 | 2017 | 266 | 1.010 |
Why?
|
| Blood Pressure Monitoring, Ambulatory | 8 | 2023 | 253 | 0.950 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 21 | 2016 | 1521 | 0.920 |
Why?
|
| Amides | 6 | 2016 | 448 | 0.890 |
Why?
|
| Kidney | 26 | 2024 | 7072 | 0.880 |
Why?
|
| Antihypertensive Agents | 21 | 2024 | 2063 | 0.810 |
Why?
|
| Aldosterone | 19 | 2022 | 868 | 0.700 |
Why?
|
| Denervation | 5 | 2023 | 277 | 0.610 |
Why?
|
| Vasodilation | 10 | 2016 | 964 | 0.610 |
Why?
|
| Internet | 8 | 2001 | 3074 | 0.600 |
Why?
|
| Angiotensinogen | 8 | 2009 | 161 | 0.590 |
Why?
|
| Renal Plasma Flow | 5 | 2008 | 27 | 0.530 |
Why?
|
| Hypertension, Renal | 3 | 2005 | 141 | 0.510 |
Why?
|
| Cerebrovascular Circulation | 3 | 2013 | 2731 | 0.510 |
Why?
|
| Beverages | 3 | 2013 | 819 | 0.500 |
Why?
|
| Renal Artery | 5 | 2023 | 368 | 0.450 |
Why?
|
| Telemedicine | 2 | 2023 | 3005 | 0.440 |
Why?
|
| Tetrazoles | 10 | 2011 | 901 | 0.440 |
Why?
|
| Endothelium, Vascular | 5 | 2016 | 4437 | 0.430 |
Why?
|
| Dipeptides | 4 | 2005 | 410 | 0.430 |
Why?
|
| Program Development | 1 | 2019 | 1297 | 0.410 |
Why?
|
| Sodium, Dietary | 6 | 2010 | 425 | 0.400 |
Why?
|
| Angiotensin I | 4 | 2008 | 56 | 0.390 |
Why?
|
| Angiotensin II Type 1 Receptor Blockers | 3 | 2011 | 435 | 0.360 |
Why?
|
| Benzimidazoles | 7 | 2007 | 858 | 0.350 |
Why?
|
| Adrenal Glands | 4 | 2002 | 556 | 0.340 |
Why?
|
| Uric Acid | 3 | 2017 | 807 | 0.340 |
Why?
|
| Diet, Sodium-Restricted | 9 | 2007 | 291 | 0.330 |
Why?
|
| Vitamin D | 5 | 2017 | 3293 | 0.330 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2010 | 280 | 0.310 |
Why?
|
| Hyperuricemia | 2 | 2017 | 224 | 0.310 |
Why?
|
| Disease Management | 1 | 2019 | 2508 | 0.300 |
Why?
|
| Reference Values | 15 | 2010 | 4920 | 0.300 |
Why?
|
| Nerve Fibers, Myelinated | 1 | 2013 | 952 | 0.290 |
Why?
|
| Probenecid | 2 | 2017 | 75 | 0.280 |
Why?
|
| Cushing Syndrome | 1 | 2008 | 242 | 0.280 |
Why?
|
| Biphenyl Compounds | 10 | 2011 | 988 | 0.270 |
Why?
|
| Alcohol Drinking | 2 | 2017 | 4012 | 0.270 |
Why?
|
| Vasoconstrictor Agents | 6 | 2008 | 651 | 0.270 |
Why?
|
| Hypercalcemia | 1 | 2008 | 421 | 0.260 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 5324 | 0.260 |
Why?
|
| Allopurinol | 2 | 2017 | 200 | 0.250 |
Why?
|
| Catechin | 1 | 2005 | 69 | 0.250 |
Why?
|
| Middle Aged | 58 | 2024 | 220175 | 0.240 |
Why?
|
| Regional Blood Flow | 6 | 2010 | 1490 | 0.230 |
Why?
|
| Pleural Neoplasms | 1 | 2008 | 609 | 0.220 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2010 | 1430 | 0.220 |
Why?
|
| Diabetes Mellitus, Type 1 | 7 | 2007 | 3451 | 0.210 |
Why?
|
| Nitric Oxide | 3 | 2012 | 2141 | 0.210 |
Why?
|
| Humans | 93 | 2024 | 760261 | 0.210 |
Why?
|
| Natriuresis | 5 | 2008 | 105 | 0.200 |
Why?
|
| Mesothelioma | 1 | 2008 | 806 | 0.200 |
Why?
|
| NG-Nitroarginine Methyl Ester | 4 | 2007 | 260 | 0.200 |
Why?
|
| American Heart Association | 2 | 2024 | 1081 | 0.200 |
Why?
|
| Albuminuria | 3 | 2010 | 659 | 0.190 |
Why?
|
| Female | 60 | 2024 | 391011 | 0.180 |
Why?
|
| Uricosuric Agents | 2 | 2017 | 32 | 0.180 |
Why?
|
| Arm | 1 | 2003 | 583 | 0.180 |
Why?
|
| p-Aminohippuric Acid | 5 | 2010 | 36 | 0.180 |
Why?
|
| Neuropsychological Tests | 1 | 2013 | 7016 | 0.180 |
Why?
|
| Feeding Behavior | 1 | 2012 | 3185 | 0.170 |
Why?
|
| Male | 56 | 2023 | 359413 | 0.170 |
Why?
|
| Nitric Oxide Synthase | 3 | 2007 | 908 | 0.160 |
Why?
|
| Information Services | 1 | 2000 | 235 | 0.160 |
Why?
|
| Enzyme Inhibitors | 4 | 2007 | 3726 | 0.150 |
Why?
|
| Blood Flow Velocity | 2 | 2013 | 1375 | 0.150 |
Why?
|
| Blood Pressure Determination | 2 | 2018 | 641 | 0.150 |
Why?
|
| Adult | 53 | 2024 | 219847 | 0.150 |
Why?
|
| Hyperemia | 2 | 2012 | 221 | 0.140 |
Why?
|
| Kidney Diseases | 1 | 2008 | 2093 | 0.140 |
Why?
|
| Vasoconstriction | 3 | 2006 | 592 | 0.140 |
Why?
|
| Manometry | 2 | 2012 | 453 | 0.140 |
Why?
|
| Vitamin D Deficiency | 2 | 2017 | 1381 | 0.140 |
Why?
|
| Treatment Outcome | 13 | 2024 | 64947 | 0.140 |
Why?
|
| Complementary Therapies | 1 | 2000 | 487 | 0.140 |
Why?
|
| Overweight | 3 | 2023 | 2421 | 0.130 |
Why?
|
| Ergocalciferols | 1 | 2017 | 111 | 0.130 |
Why?
|
| Infusions, Intravenous | 4 | 2010 | 2235 | 0.130 |
Why?
|
| Glomerular Filtration Rate | 9 | 2016 | 2178 | 0.130 |
Why?
|
| Hypercholesterolemia | 1 | 2023 | 1155 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 9 | 2016 | 10829 | 0.130 |
Why?
|
| Polymorphism, Genetic | 4 | 2008 | 4286 | 0.130 |
Why?
|
| Receptor, Angiotensin, Type 1 | 2 | 2009 | 148 | 0.120 |
Why?
|
| Sodium | 3 | 2010 | 1601 | 0.120 |
Why?
|
| Nurses | 1 | 2024 | 2468 | 0.120 |
Why?
|
| Carbamates | 1 | 2016 | 192 | 0.120 |
Why?
|
| Pulsatile Flow | 2 | 2006 | 320 | 0.110 |
Why?
|
| Thiazoles | 2 | 2005 | 1509 | 0.110 |
Why?
|
| Aging | 5 | 2006 | 8641 | 0.110 |
Why?
|
| Pandemics | 2 | 2023 | 8621 | 0.110 |
Why?
|
| Double-Blind Method | 6 | 2017 | 12412 | 0.100 |
Why?
|
| Diabetic Nephropathies | 4 | 2005 | 988 | 0.100 |
Why?
|
| Plethysmography | 1 | 2012 | 174 | 0.100 |
Why?
|
| Medical Informatics | 1 | 1999 | 733 | 0.100 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 1902 | 0.100 |
Why?
|
| Vitamins | 2 | 2017 | 1635 | 0.100 |
Why?
|
| Medication Adherence | 1 | 2023 | 2163 | 0.090 |
Why?
|
| Sodium Chloride, Dietary | 4 | 2011 | 293 | 0.090 |
Why?
|
| Sex Factors | 5 | 2007 | 10530 | 0.090 |
Why?
|
| Piperazines | 2 | 2005 | 2520 | 0.090 |
Why?
|
| Psychotherapy, Brief | 1 | 2011 | 118 | 0.090 |
Why?
|
| Patient Education as Topic | 1 | 1999 | 2311 | 0.080 |
Why?
|
| Cardiovascular Diseases | 3 | 2020 | 15740 | 0.080 |
Why?
|
| Environmental Exposure | 1 | 2024 | 4404 | 0.080 |
Why?
|
| Aged | 18 | 2023 | 168995 | 0.080 |
Why?
|
| Candy | 1 | 2007 | 36 | 0.080 |
Why?
|
| Secretory Vesicles | 1 | 2008 | 128 | 0.080 |
Why?
|
| Prospective Studies | 5 | 2024 | 54263 | 0.070 |
Why?
|
| Calmodulin-Binding Proteins | 1 | 2009 | 232 | 0.070 |
Why?
|
| Genotype | 6 | 2008 | 12959 | 0.070 |
Why?
|
| Flavanones | 1 | 2007 | 74 | 0.070 |
Why?
|
| Societies, Medical | 1 | 2000 | 3903 | 0.070 |
Why?
|
| Hemodynamics | 7 | 2005 | 4169 | 0.070 |
Why?
|
| Piperidines | 1 | 2016 | 1650 | 0.070 |
Why?
|
| Postmenopause | 3 | 2009 | 2503 | 0.070 |
Why?
|
| Cough | 1 | 2011 | 595 | 0.070 |
Why?
|
| Edema | 1 | 2011 | 772 | 0.070 |
Why?
|
| Dietary Supplements | 2 | 2017 | 3389 | 0.070 |
Why?
|
| Enalapril | 2 | 2000 | 313 | 0.070 |
Why?
|
| Fruit | 1 | 2012 | 1162 | 0.070 |
Why?
|
| Vegetables | 1 | 2012 | 1198 | 0.070 |
Why?
|
| Color | 1 | 2007 | 298 | 0.070 |
Why?
|
| Brain | 1 | 2013 | 26912 | 0.070 |
Why?
|
| Hydrocortisone | 3 | 2001 | 1798 | 0.070 |
Why?
|
| Genetic Linkage | 2 | 2005 | 2381 | 0.070 |
Why?
|
| Family Health | 2 | 2002 | 1258 | 0.070 |
Why?
|
| Administration, Oral | 2 | 2016 | 4044 | 0.060 |
Why?
|
| Pilot Projects | 1 | 2019 | 8553 | 0.060 |
Why?
|
| Risk-Taking | 1 | 2011 | 1000 | 0.060 |
Why?
|
| Public Health | 1 | 2018 | 2655 | 0.060 |
Why?
|
| Angiotensins | 1 | 2005 | 143 | 0.060 |
Why?
|
| Psychomotor Performance | 1 | 2013 | 1876 | 0.060 |
Why?
|
| Brachial Artery | 2 | 2016 | 368 | 0.060 |
Why?
|
| Food Labeling | 1 | 2007 | 181 | 0.060 |
Why?
|
| Medical Records | 1 | 2010 | 1407 | 0.060 |
Why?
|
| Blood Volume | 1 | 2006 | 550 | 0.060 |
Why?
|
| Dementia, Vascular | 1 | 2006 | 125 | 0.060 |
Why?
|
| Age Factors | 5 | 2008 | 18415 | 0.060 |
Why?
|
| Systole | 2 | 2003 | 947 | 0.060 |
Why?
|
| Endovascular Procedures | 1 | 2018 | 2135 | 0.060 |
Why?
|
| Diastole | 2 | 2003 | 788 | 0.060 |
Why?
|
| Pulse | 1 | 2003 | 218 | 0.060 |
Why?
|
| Hormone Replacement Therapy | 1 | 2009 | 756 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 5 | 2011 | 12281 | 0.050 |
Why?
|
| Quality of Health Care | 1 | 2018 | 4361 | 0.050 |
Why?
|
| Fingers | 1 | 2006 | 505 | 0.050 |
Why?
|
| Osmolar Concentration | 1 | 2004 | 662 | 0.050 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 820 | 0.050 |
Why?
|
| Contraceptives, Oral | 1 | 2005 | 554 | 0.050 |
Why?
|
| Phenotype | 6 | 2008 | 16543 | 0.050 |
Why?
|
| Body Mass Index | 6 | 2023 | 12901 | 0.050 |
Why?
|
| Linear Models | 3 | 2007 | 5876 | 0.050 |
Why?
|
| Homeostasis | 2 | 2010 | 3305 | 0.050 |
Why?
|
| Coronary Circulation | 1 | 2007 | 1578 | 0.050 |
Why?
|
| Predictive Value of Tests | 3 | 2008 | 15273 | 0.050 |
Why?
|
| Potassium, Dietary | 1 | 2001 | 104 | 0.050 |
Why?
|
| Mast Cells | 1 | 2008 | 1428 | 0.050 |
Why?
|
| United States | 5 | 2024 | 72363 | 0.050 |
Why?
|
| Receptor, Angiotensin, Type 2 | 1 | 2001 | 60 | 0.050 |
Why?
|
| Lisinopril | 1 | 2001 | 55 | 0.050 |
Why?
|
| Adolescent | 10 | 2018 | 87747 | 0.050 |
Why?
|
| Blood Glucose | 3 | 2007 | 6375 | 0.050 |
Why?
|
| Potassium | 2 | 2002 | 1318 | 0.050 |
Why?
|
| Kidney Glomerulus | 1 | 2003 | 568 | 0.040 |
Why?
|
| Kidney Function Tests | 3 | 2009 | 680 | 0.040 |
Why?
|
| Renal Veins | 1 | 2000 | 102 | 0.040 |
Why?
|
| Alcoholism | 1 | 2010 | 1961 | 0.040 |
Why?
|
| Drug Design | 1 | 2005 | 1062 | 0.040 |
Why?
|
| MEDLINE | 1 | 1999 | 119 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2000 | 295 | 0.040 |
Why?
|
| Vasodilator Agents | 1 | 2002 | 977 | 0.040 |
Why?
|
| Angiotensin Receptor Antagonists | 2 | 2002 | 1025 | 0.040 |
Why?
|
| Patient Selection | 1 | 2010 | 4276 | 0.040 |
Why?
|
| Acrylates | 1 | 1997 | 79 | 0.040 |
Why?
|
| Infusions, Parenteral | 1 | 1997 | 404 | 0.030 |
Why?
|
| Radioimmunoassay | 1 | 2016 | 866 | 0.030 |
Why?
|
| Risk Factors | 8 | 2020 | 74269 | 0.030 |
Why?
|
| Cognition | 1 | 2013 | 6948 | 0.030 |
Why?
|
| Young Adult | 5 | 2023 | 58673 | 0.030 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 1997 | 361 | 0.030 |
Why?
|
| Clinical Trials as Topic | 2 | 2022 | 8058 | 0.030 |
Why?
|
| Gout Suppressants | 1 | 2016 | 178 | 0.030 |
Why?
|
| Time Factors | 5 | 2017 | 40133 | 0.030 |
Why?
|
| Diabetes Mellitus | 3 | 2011 | 5884 | 0.030 |
Why?
|
| Mass Screening | 1 | 2010 | 5422 | 0.030 |
Why?
|
| Demography | 1 | 1999 | 1650 | 0.030 |
Why?
|
| Ultrasonography, Doppler | 1 | 2016 | 466 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2018 | 1577 | 0.030 |
Why?
|
| Ultrasonography | 2 | 2018 | 5960 | 0.030 |
Why?
|
| Health Education | 1 | 2001 | 1049 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2023 | 80301 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2024 | 12532 | 0.030 |
Why?
|
| Patient-Centered Care | 1 | 2023 | 1416 | 0.030 |
Why?
|
| Exercise | 1 | 2010 | 5783 | 0.030 |
Why?
|
| Cholesterol, LDL | 1 | 2023 | 2422 | 0.030 |
Why?
|
| Thiophenes | 1 | 1997 | 587 | 0.030 |
Why?
|
| Peptides | 1 | 2005 | 4358 | 0.030 |
Why?
|
| Menopause | 2 | 2000 | 1640 | 0.030 |
Why?
|
| Premenopause | 1 | 1997 | 1039 | 0.030 |
Why?
|
| Publishing | 1 | 2000 | 837 | 0.030 |
Why?
|
| Consensus | 1 | 2022 | 3106 | 0.030 |
Why?
|
| Adrenocorticotropic Hormone | 1 | 1994 | 619 | 0.020 |
Why?
|
| Glucose | 1 | 2003 | 4361 | 0.020 |
Why?
|
| Boston | 2 | 2017 | 9282 | 0.020 |
Why?
|
| Imidazoles | 1 | 1997 | 1178 | 0.020 |
Why?
|
| Endocrine Glands | 1 | 1991 | 101 | 0.020 |
Why?
|
| Catheter Ablation | 1 | 2024 | 2755 | 0.020 |
Why?
|
| Obesity | 2 | 2023 | 12915 | 0.020 |
Why?
|
| Air Pollution | 1 | 2024 | 2316 | 0.020 |
Why?
|
| Syndrome | 1 | 1997 | 3278 | 0.020 |
Why?
|
| Case-Control Studies | 2 | 2008 | 22041 | 0.020 |
Why?
|
| Central Nervous System Depressants | 1 | 2011 | 164 | 0.020 |
Why?
|
| Diet | 1 | 2008 | 8008 | 0.020 |
Why?
|
| Creatinine | 2 | 2008 | 1906 | 0.020 |
Why?
|
| Down-Regulation | 1 | 2017 | 2918 | 0.020 |
Why?
|
| Sex Characteristics | 1 | 2000 | 2627 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2009 | 15766 | 0.020 |
Why?
|
| Leukemia, Mast-Cell | 1 | 2008 | 13 | 0.020 |
Why?
|
| Cohort Studies | 3 | 2024 | 41317 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2016 | 4900 | 0.020 |
Why?
|
| Interview, Psychological | 1 | 2011 | 812 | 0.020 |
Why?
|
| Creatine | 1 | 2010 | 426 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2011 | 6499 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 1997 | 2696 | 0.020 |
Why?
|
| Culture Media | 1 | 2008 | 899 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 1999 | 3242 | 0.020 |
Why?
|
| Inulin | 2 | 1999 | 68 | 0.020 |
Why?
|
| Calcium, Dietary | 1 | 2008 | 531 | 0.020 |
Why?
|
| Gastroparesis | 1 | 2007 | 137 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2016 | 39254 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2000 | 8018 | 0.020 |
Why?
|
| Aged, 80 and over | 1 | 2010 | 58947 | 0.020 |
Why?
|
| Ethanol | 1 | 2011 | 1323 | 0.020 |
Why?
|
| Sodium Chloride | 1 | 2006 | 596 | 0.010 |
Why?
|
| Water-Electrolyte Balance | 1 | 2005 | 334 | 0.010 |
Why?
|
| Infertility | 1 | 2011 | 655 | 0.010 |
Why?
|
| Thyroid Diseases | 1 | 2007 | 386 | 0.010 |
Why?
|
| Diabetic Neuropathies | 1 | 2007 | 406 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2000 | 7468 | 0.010 |
Why?
|
| Animals | 4 | 2001 | 167940 | 0.010 |
Why?
|
| Cross-Sectional Studies | 3 | 2010 | 25928 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2007 | 782 | 0.010 |
Why?
|
| Sensitivity and Specificity | 2 | 2010 | 14656 | 0.010 |
Why?
|
| Diabetic Angiopathies | 1 | 2007 | 822 | 0.010 |
Why?
|
| Chi-Square Distribution | 1 | 2008 | 3466 | 0.010 |
Why?
|
| France | 1 | 2003 | 511 | 0.010 |
Why?
|
| Data Collection | 1 | 2011 | 3317 | 0.010 |
Why?
|
| Osteoporosis | 1 | 2011 | 1600 | 0.010 |
Why?
|
| Italy | 1 | 2003 | 840 | 0.010 |
Why?
|
| Algorithms | 1 | 2020 | 13967 | 0.010 |
Why?
|
| Motor Activity | 1 | 2010 | 2687 | 0.010 |
Why?
|
| Nuclear Family | 1 | 2000 | 313 | 0.010 |
Why?
|
| Zona Glomerulosa | 1 | 1999 | 87 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2008 | 6361 | 0.010 |
Why?
|
| Glucose Clamp Technique | 1 | 1999 | 263 | 0.010 |
Why?
|
| Complement Pathway, Alternative | 1 | 1998 | 116 | 0.010 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2006 | 36247 | 0.010 |
Why?
|
| Age of Onset | 1 | 2005 | 3302 | 0.010 |
Why?
|
| Diabetic Retinopathy | 1 | 2007 | 1268 | 0.010 |
Why?
|
| Massachusetts | 1 | 2010 | 8805 | 0.010 |
Why?
|
| Hematocrit | 1 | 1999 | 630 | 0.010 |
Why?
|
| Observer Variation | 1 | 2003 | 2596 | 0.010 |
Why?
|
| Risk | 1 | 2009 | 9629 | 0.010 |
Why?
|
| Statistics as Topic | 1 | 2003 | 2363 | 0.010 |
Why?
|
| Pregnancy Complications | 1 | 2010 | 2940 | 0.010 |
Why?
|
| Comorbidity | 1 | 2011 | 10552 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2001 | 1112 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2001 | 1617 | 0.010 |
Why?
|
| Posture | 1 | 1999 | 954 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2005 | 12156 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2008 | 16905 | 0.010 |
Why?
|
| Incidence | 1 | 2008 | 21378 | 0.010 |
Why?
|
| Pregnancy | 1 | 2010 | 29725 | 0.000 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2009 | 17766 | 0.000 |
Why?
|
| Models, Biological | 1 | 2002 | 9468 | 0.000 |
Why?
|
| Heart | 1 | 1998 | 4392 | 0.000 |
Why?
|
| Insulin | 1 | 1999 | 6592 | 0.000 |
Why?
|